Heart failure is accompanied by severely impaired ␤-adrenergic receptor (␤AR) function, which includes loss of ␤AR density and functional uncoupling of remaining receptors. An important mechanism for the rapid desensitization of ␤AR function is agonist-stimulated receptor phosphorylation by the ␤AR kinase (␤ARK1), an enzyme known to be elevated in failing human heart tissue. To investigate whether alterations in ␤AR function contribute to the development of myocardial failure, transgenic mice with cardiac-restricted overexpression of either a peptide inhibitor of ␤ARK1 or the ␤ 2 AR were mated into a genetic model of murine heart failure (MLP ؊͞؊ ). In vivo cardiac function was assessed by echocardiography and cardiac catheterization. Both MLP ؊͞؊ and MLP ؊͞؊ ͞␤ 2 AR mice had enlarged left ventricular (LV) chambers with significantly reduced fractional shortening and mean velocity of circumferential fiber shortening. In contrast, MLP ؊͞؊ ͞␤ARKct mice had normal LV chamber size and function. Basal LV contractility in the MLP ؊͞؊ ͞␤ARKct mice, as measured by LV dP͞dtmax, was increased significantly compared with the MLP ؊͞؊ mice but less than controls. Importantly, heightened ␤AR desensitization in the MLP ؊͞؊ mice, measured in vivo (responsiveness to isoproterenol) and in vitro (isoproterenol-stimulated membrane adenylyl cyclase activity), was completely reversed with overexpression of the ␤ARK1 inhibitor. We report here the striking finding that overexpression of this inhibitor prevents the development of cardiomyopathy in this murine model of heart failure. These findings implicate abnormal ␤AR-G protein coupling in the pathogenesis of the failing heart and point the way toward development of agents to inhibit ␤ARK1 as a novel mode of therapy.
One of the most important mechanisms for rapidly regulating ␤-adrenergic receptor (␤AR) function is agonist-stimulated receptor phosphorylation by G protein-coupled receptor kinases (GRKs) resulting in decreased sensitivity to further catecholamine stimulation (1, 2) . ␤ARK1 is a member of the multigene GRK family that regulates a wide variety of receptors that couple to heterotrimeric G proteins (1, 2) . Desensitization of agonistoccupied receptors by the cytosolic ␤AR kinase (␤ARK1) requires a membrane-targeting event before its activation and receptor phosphorylation, which is mediated by a direct physical interaction between residues within the carboxyl terminus of ␤ARK1 and the dissociated membrane-anchored ␤␥ subunits of G proteins (G␤␥) (3, 4) .
Heart failure is a disease characterized by left ventricular (LV) dysfunction associated with a complex of symptoms that relate to inadequate perfusion of tissues and pulmonary congestion. Although the fundamental molecular abnormality that causes this progressive deterioration in cardiac function is unknown, one of the leading candidates is abnormal ␤AR signaling. Chronic human heart failure is characterized by severely attenuated ␤AR signaling, resulting from diminished receptor number and impaired receptor function (5), leading to inotropic subsensitivity and impaired exercise tolerance (6) . Increased levels of ␤ARK1, found in failing human heart tissue, have been postulated to account for impaired receptor function in response to agonist stimulation (7, 8) . In animal models of heart disease, prominent ␤AR desensitization recently has been shown to be associated with heightened levels of ␤ARK1 (9, 10) . Our findings in transgenic mice that overexpress different members of the GRK family demonstrate how the up-regulation of ␤ARK1 in the diseased heart could markedly alter ␤AR function through receptor desensitization (9, 11, 12) . Importantly, inhibition of myocardial ␤ARK1 activity because of cardiac-targeted expression of a peptide inhibitor of ␤ARK1 (␤ARKct) led to enhanced contractility demonstrating the critical role of ␤ARK1 in normal heart function (11) . The ␤ARKct is composed of the last 195 aa of ␤ARK1, which contains the binding site for G␤␥ and competes with endogenous ␤ARK1 for G␤␥ membrane translocation and activation (11) .
A limitation in addressing mechanistic pathways in the setting of heart failure has been the lack of a well characterized model of murine heart failure that has fidelity to the human condition (13) . Recently, a genetic model of murine-dilated cardiomyopathy has been described that involves ablation of a musclerestricted gene that encodes the muscle LIM protein (MLP Ϫ͞Ϫ ) (14) . Our goal was to determine whether abnormalities in ␤AR signaling in the failing heart play a causative role in the progressive deterioration in cardiac function and whether reversal of these alterations can lead to improvement of cardiac function. To accomplish this, our strategy was to mate transgenic mice with cardiac-targeted overexpression of either the ␤ARKct (11) or the ␤ 2 AR (15) into the MLP Ϫ͞Ϫ model of heart failure.
METHODS
Experimental Animals. MLP Ϫ͞Ϫ mice were mated with transgenic mice with cardiac-targeted overexpression of the ␤ARKct (11). F1 pups generated from an MLP Ϫ͞Ϫ ϫ ␤ARKct(t͞t) homozygote cross were mated to create the MLP ϩ͞Ϫ ͞ ␤ARKct(t͞0) double heterozygote (where t represents the presence of a transgene). F2 offspring generated from a MLP Ϫ͞Ϫ ϫ MLP ϩ͞Ϫ ͞␤ARKct(t͞0) double heterozygote mating generated mice that were MLP Ϫ͞Ϫ and MLP Ϫ͞Ϫ ͞␤ARKct(t͞0) with the remainder of the pups heterozygous for MLP with and without the ␤ARKct transgene. F3 offspring were generated by back-crossing a MLP Ϫ͞Ϫ ͞␤ARKct(t͞0) mouse into the MLP Ϫ͞Ϫ parent to generate MLP Ϫ͞Ϫ and MLP Ϫ͞Ϫ ͞␤ARKct(t͞0) littermates. A similar strategy was used to generate MLP Ϫ͞Ϫ ͞␤ 2 AR(t͞0) gene-targeted mice. The genotype of the various gene-targeted crosses was determined by PCR on genomic DNA isolated from tail biopsies as described previously (11, 14, 15) . Expression of the ␤ARKct peptide in hearts of MLP Ϫ͞Ϫ ͞␤ARKct mice was confirmed by immunoblotting using a polyclonal antibody directed against the C terminus of ␤ARK1. The animals in this study were handled according to approved protocols and the animal welfare regulations of the University of North Carolina at Chapel Hill, Duke University, and the University of California at San Diego.
Transthoracic Echocardiography. Echocardiography was performed in anesthetized mice (2.5% avertin, 14 l͞g intraperitoneally) by using an Apogee CX echocardiograph (Interspec-ATL, Bothell, WA) as described previously (16) . Echocardiography was performed in nonlittermate control MLP ϩ͞ϩ mice by using a different anesthesia (mixture of 100 mg͞kg ketamine and 5 mg͞kg xylazine, i.p.), which is associated with a lower heart rate and therefore mean velocity of circumferential fiber shortening (mean Vcf) (16) .
Cardiac Catheterization. Hemodynamic evaluation in intact mice was performed as described previously (9) . Mice were anesthetized with a mixture of ketamine (100 mg͞kg) and xylazine (2.5 mg͞kg) and, after endotracheal intubation, were connected to a rodent ventilator. After bilateral vagotomy, the left carotid artery was cannulated with a flame-stretched PE-50 catheter connected to a modified P-50 Statham transducer (17) . A 1.4 French (0.46 mm) high-fidelity micromanometer catheter (Millar Instruments, Houston, TX) was inserted into the right carotid and advanced retrograde into the LV. Hemodynamic measurements were recorded at baseline and 45-60 sec after injection of incremental doses of isoproterenol (9) .
Adenylyl Cyclase Activity and ␤AR Binding. Adenylyl cyclase activity and ␤AR binding were performed from myocardial sarcolemmal membranes (9, 11) . For cyclase activity, membranes (30-40 g protein) were incubated for 15 min at 37°C with [␣ -32 P]ATP under basal conditions or indicated agonists and cAMP was quantified (9, 11) . Total ␤ AR density was determined by incubating 25 g of sarcolemmal membranes with a saturating concentration of [ 125 I]cyanopindolol and 20 M alprenolol to define nonspecific binding (9, 11) .
Immunoblotting. Immunodetection of myocardial levels of ␤ARK1 was performed on cytosolic extracts after immunoprecipitation by using a monoclonal ␤ARK1͞2 antibody as described previously (9, 11, 18) . The Ϸ80-kDa ␤ARK1 protein was visualized with the mAb raised against an epitope within the carboxyl terminus of ␤ARK1 and chemiluminescent detection of antimouse IgG conjugated with horseradish peroxidase (ECL, Amersham). GRK activity was measured in myocardial membranes by using rhodopsin-enriched rod outer segment membranes as an in vitro substrate and [␥-32 P]ATP as described previously (9, 11, 18) . [ 32 P] incorporation into rhodopsin was quantified by using a using a Molecular Dynamics PhosphorImager (9, 11, 18) .
Histological Analysis of Gene-Targeted Mouse Hearts. Unfixed myocardial cryosections were obtained and histological staining of myocytes was done with Masson's trichrome by standard protocols (14) .
Statistical Analysis. Data were expressed as mean Ϯ SEM. To test for statistical differences in echocardiographic data between all groups, a one-factor ANOVA was performed accompanied by a Newman-Keuls post hoc analysis when appropriate. Hemodynamic data were analyzed with a repeated-measures ANOVA, and post hoc analysis with regard to differences in mean values between the groups at a specific dose was conducted with a Newman-Keuls test. Cyclase activity was analyzed with a repeated-measures ANOVA. ␤AR density and NaF stimulation were determined with a one-factor ANOVA. A Student's t test was used to test differences in the level of myocardial ␤ARK1.
RESULTS
To investigate whether abnormalities in ␤AR signaling are responsible for the progressive deterioration in cardiac function in the failing heart, we used a strategy whereby transgenic mice with cardiac-targeted overexpression of either the ␤ARKct (11) or the ␤ 2 AR (15) were mated into the MLP Ϫ͞Ϫ model of heart failure. In vivo cardiac function in these novel, dual gene-targeted mice was assessed by echocardiography. MLP Ϫ͞Ϫ mice have enlarged cardiac chambers with depressed function as shown by the increase in LV end-diastolic and end-systolic dimension associated with a reduction in fractional shortening (FS) and mean Vcf (Table 1 and Fig. 1A ). Cardiac overexpression of the ␤ 2 AR in the MLP-deficient background did not influence the development of the dilated cardiomyopathic phenotype, because cardiac chambers remained enlarged whereas FS and mean Vcf continued to be depressed compared with MLP Ϫ͞Ϫ littermates ( Table 1 and Fig. 1 A) . In striking contrast, cardiac-targeted ␤ARK1 inhibition through overexpression of the ␤ARKct prevented the deteriora- Table 1 . Transgene overexpression in MLP-deficient mice: In vivo echocardiographic assessment 
Analysis of in vivo cardiac size and function by echocardiography in gene-targeted mice. Mating of transgenic mice with cardiac overexpression of the ␤2AR or a a ␤ARKct into the MLP-deficient background resulted in mice homozygous for the MLP gene ablation and heterozygous for either the ␤2AR (MLP Ϫ͞Ϫ ͞␤2AR) or the ␤ARKct (MLP Ϫ͞Ϫ ͞␤ARKct), MLP Ϫ͞Ϫa and MLP Ϫ͞Ϫb are littermates for the ␤2AR and ␤ARKct cross, respectively. MLP ϩ͞ϩ are adult nonlittermate wild-type mice of the same genetic background that were used as controls. LVEDD, left ventricular end diastolic dimension; LVESD, left venrtricular end systolic dimension; HR, heart rate; FS, fractional shortening calculated as (LVEDD Ϫ LVESD)͞LVEDD ϫ 100; SEPth, septal wall thickness; PWth, posterior wall thickness; mean Vcf, mean velocity of circumferential fiber shortening; mean Vcfc, heart rate-corrected mean Vcf; BW, body weight. *P Ͻ 0.0005, † P Ͻ 0.01, MLP Ϫ͞Ϫ ͞␤ARKct and MLP ϩ͞ϩ vs. either MLP Ϫ͞Ϫb or MLP Ϫ͞Ϫa ; ‡ P Ͻ 0.01, MLP(ϩ͞ϩ) vs. MLP Ϫ͞Ϫ ͞␤ARKct. The MLP Ϫ͞Ϫ ͞␤ARKct and MLP Ϫ͞Ϫa mice were significantly older than the other groups. (P Ͻ 0.05). MLP ϩ͞ϩ mice underwent echocardiography with a different anesthesia, accounting for the slower heart rate and therefore a lower mean Vcf (16) . However, for the echocardiographic parameters measured, no significant differences in any of the other variables were found between the MLP Ϫ͞Ϫ ͞␤2AR and their MLP Ϫ͞Ϫa littermates, or between the MLP Ϫ͞Ϫa and MLP Ϫ͞Ϫb littermate groups. Therefore, for subsequent analysis of echocardiographic data, the MLR Ϫ͞Ϫ groups were pooled. tion in cardiac function (Table 1 and Fig. 1 A) . In MLP Ϫ͞Ϫ ͞ ␤ARKct mice compared with age-matched MLP Ϫ͞Ϫ littermates, LV end-diastolic and end-systolic dimensions were significantly smaller, whereas FS and mean Vcf were significantly higher, indicating preserved cardiac function (Table 1 and Fig. 1 A) .
To determine whether changes in ventricular function were time-dependent, serial echocardiography was performed in the three groups of gene-targeted mice. MLP Ϫ͞Ϫ mice and MLP Ϫ͞Ϫ ͞␤ 2 AR under 6 months of age have enlarged LV chambers with depressed cardiac function (reduced FS and mean Vcfc) (Fig. 1B) . In contrast, MLP Ϫ͞Ϫ ͞␤ARKct mice under 6 months of age have normal LV chamber size and function (Fig. 1B) . This beneficial effect of the ␤ARKct on cardiac function persisted as the mice grew older, whereas little change and even some deterioration occurred in the MLP Ϫ͞Ϫ and MLP Ϫ͞Ϫ ͞␤ 2 AR mice (Fig. 1B) . Individual data points are plotted for FS to determine whether a serial change in cardiac function occurred over a 3-month period (Fig. 1C) . Whereas MLP Ϫ͞Ϫ animals had reduced FS that did not change over time, the presence of additional cardiac ␤ 2 ARs (MLP Ϫ͞Ϫ ͞␤ 2 AR) resulted in deterioration of FS in the majority of mice. In contrast, FS was preserved in the MLP Ϫ͞Ϫ ͞␤ARKct mice and remained in the normal range over the 3-month study interval (Fig. 1C) .
To determine whether overexpression of the ␤ARKct can reverse the marked ␤AR desensitization associated with the MLP Ϫ͞Ϫ mice, we performed cardiac catheterization in intact anesthetized mice. LV contractility (assessed by LV dP͞dtmax) at baseline in the MLP Ϫ͞Ϫ ͞␤ARKct mice was modestly but significantly increased compared with the MLP Ϫ͞Ϫ , but was less than nonlittermate wild-type MLP ϩ͞ϩ control mice (Fig. 2A) . However, the abnormal response to isoproterenol stimulation, characteristic of the MLP Ϫ͞Ϫ animals, was reversed completely with ␤ARKct overexpression (Fig. 2 A and B) . This response to isoproterenol was essentially identical to that in the wild-type MLP ϩ͞ϩ mice and is consistent with a mechanism of ␤ARK1 inhibition that preserves normal ␤AR-G protein coupling (Fig. 2  A and B) . Similarly, the increase in heart rate from baseline in response to ␤AR stimulation was preserved in the MLP Ϫ͞Ϫ ͞ ␤ARKct mice although basal heart rate was lower than in wild-type mice (Fig. 2C) . Furthermore, the markedly elevated LV end diastolic pressure in the MLP Ϫ͞Ϫ mice (an indication of the severe impairment of cardiac function in these animals) was normalized by chronic ␤ARKct expression (Fig. 2D) ␤AR density and adenylyl cyclase activity were determined in cardiac membranes prepared from the various gene-targeted lines. ␤AR density was reduced significantly by 54% in the MLP Ϫ͞Ϫ compared with wild-type hearts and was associated with marked attenuation of isoproterenol-stimulated adenylyl cyclase activity, indicating severe impairment of ␤AR coupling (Table 2) . Although ␤AR density also was reduced in MLP Ϫ͞Ϫ ͞␤ARKct compared with wild-type mice, isoproterenol-stimulated adenylyl cyclase activity was enhanced significantly and intermediate between wild-type and MLP-deficient mice (Table 2) . Importantly, fold increase in membrane cyclase activity with isoproterenol stimulation in the MLP Ϫ͞Ϫ ͞␤ARKct hearts was 2.8 vs. 2.6 in the wild-type hearts and 1.7 in the MLP Ϫ͞Ϫ hearts, indicating restitution toward normal G protein coupling. These biochemical findings are completely concordant with the in vivo data (Fig. 2) and indicate that the functional uncoupling of ␤ARs seen in the failing MLP Ϫ͞Ϫ hearts can be prevented with chronic overexpression in vivo of the ␤ARKct. This is also consistent with the LV weight data obtained after terminal hemodynamic study where a significant decrease in LV mass in the MLP Ϫ͞Ϫ ͞␤ARKct hearts (n ϭ 8) compared with MLP Ϫ͞Ϫ hearts (n ϭ 15) was observed (LV weight to tibia length ratio, 6.5 Ϯ 0.3 vs. 7.8 Ϯ 0.3 mg͞mm, P Ͻ 0.02). LV mass in the MLP Ϫ͞Ϫ ͞␤ARKct hearts was slightly, but not significantly, higher than that in the control hearts (MLP ϩ͞ϩ , 5.5 Ϯ 0.3 mg͞mm, n ϭ 6).
FIG. 2.
In vivo assessment of ␤-AR responsiveness. Cardiac catheterization was performed in intact, anesthetized mice. Parameters are shown at baseline and after progressive infusion of isoproterenol in MLP Ϫ͞Ϫ (E), n ϭ 15, MLP Ϫ͞Ϫ ͞␤ARKct (F), n ϭ 7, and wild-type MLP ϩ͞ϩ (ᮀ), n ϭ 6, mice. A significant between-group main effect in response to isoproterenol was found for LV dP͞dtmax, P Ͻ 0.00001 (A); heart rate, P ϭ 0.05 (C); and LV end diastolic pressure, P Ͻ 0.05 (D). The pattern of change between groups was statistically significantly for LV dP͞dtmax, P Ͻ 0.00001 (A) and ⌬LV dP͞dtmax, P Ͻ 0.00001 (B).
FIG. 3. Assessment of myocardial ␤ARK1 levels and activity. (A)
␤ARK1 protein levels of myocardial extracts were determined by protein immunoblotting. Shown is a representative experiment with two hearts from each gene-targeted mouse. Similar results were obtained in two more hearts in each group. ␤ARK1 protein levels were Ϸ2-fold higher in the MLP Ϫ͞Ϫ hearts compared with MLP ϩ͞ϩ hearts (P Ͻ 0.05) whereas myocardial ␤ARK1 levels in the MLP Ϫ͞Ϫ ͞␤ARKct hearts were not significantly different than wild-type hearts. (B) Rhodopsin-enriched rod outer segment membranes were used as a substrate for membrane myocardial GRK activity and 32 P incorporation was quantified from dried gels. The data represent a sample size of four to six hearts in each group. ‫,ء‬ P Ͻ 0.05 vs. MLP ϩ͞ϩ ; #, P Ͻ 0.03 vs. MLP Ϫ͞Ϫ . Because ␤ARK1 levels and activity are enhanced in human heart failure, we sought to determine whether myocardial ␤ARK1 levels are increased in the MLP Ϫ͞Ϫ mouse, which could contribute to the marked ␤AR uncoupling observed. Myocardial ␤ARK1 levels were assessed by immunoprecipitation of soluble heart extracts. Cytosolic ␤ARK1 levels were Ϸ2-fold higher in the hearts of MLP Ϫ͞Ϫ animals compared with MLP ϩ͞ϩ animals (Fig.  3A) . Furthermore, we measured enzyme activity in extracts from myocardial membranes, because this is where ␤ARK1 exerts its regulatory actions. We found membrane GRK activity to be significantly increased and parallel to the protein data (Fig. 3B) . Immunoblotting for a second GRK found in the heart, GRK5, revealed no difference in expression between the different lines of mice (data not shown), indicating that the increase in membrane kinase activity can be accounted for by translocated ␤ARK1 to the membrane. Taken together, these data show that chronic myocardial expression of the ␤ARKct eliminates development of the severe heart failure phenotype and prevents the up-regulation of ␤ARK1 as demonstrated by both protein immunoblotting and GRK activity (Fig. 3 A and B) .
The deleterious effects of ␤ 2 AR overexpression in the MLP Ϫ͞Ϫ mice is demonstrated further by the marked adverse effect on survival. Cumulative survival probability for MLP Ϫ͞Ϫ ͞␤ 2 AR mice (n ϭ 11) was shortened significantly such that over a 9-month follow-up period the probability of survival was approximately 12% compared with 80% for the MLP Ϫ͞Ϫ mice (n ϭ 19; P Ͻ 0.0001, Mantel-Haenszel 2 statistic, MLP Ϫ͞Ϫ ͞␤ 2 AR vs. MLP Ϫ͞Ϫ ). Over the same time period only 1 of 10 MLP Ϫ͞Ϫ ͞ ␤ARKct mice died, which occurred at 7 months of age, and did not differ significantly from the MLP Ϫ͞Ϫ mice. These data clearly demonstrate that enhancing ␤AR signaling through marked overexpression of ␤ 2 ARs in this murine model of myocardial failure has deleterious consequences that are accompanied by persistent cardiac chamber enlargement, progressive deterioration in cardiac function, and diminished survival. In contrast, reversal of ␤AR desensitization through chronic overexpression of a ␤ARK1 inhibitor essentially prevents the development of heart failure in MLP Ϫ͞Ϫ mice.
We also examined the hearts of these gene-targeted mice histologically and found that the characteristic fibrosis found in the MLP Ϫ͞Ϫ hearts (14) did not seem to lessen because of the presence of the ␤ARKct (Fig. 4) . This is not surprising and suggests that the histopathological changes in the MLP Ϫ͞Ϫ hearts are a result of the absence of the cytoskeletal MLP protein and are not a result of the dilated cardiomyopathy per se.
DISCUSSION
The above echocardiographic and hemodynamic findings suggest that GRK-mediated ␤AR desensitization plays a causative role in the development of heart failure in this animal model. Moreover, they indicate the potential for novel therapeutic strategies that aim to modulate the activity level of myocardial ␤ARK1 during the course of the cardiomyopathic process. We have chosen to use a genetic-based model of dilated cardiomyopathy through targeted disruption of the muscle LIM protein gene, which closely resembles the phenotype of human dilated cardiomyopathy (14) . The MLP is a conserved positive regulator of myogenic differentiation, and recent findings suggest that it may act as a molecular adapter to promote protein assembly along the actin-based cytoskeleton. Hearts from MLP-deficient mice are characterized by marked disruption of cardiomyocyte architecture (14) . Human heart failure also is a disease of cardiac muscle characterized by alterations in cardiomyocyte shape (19) , cytoskeletal abnormalities (20) , and ␤AR signaling (5), which supports our use of the MLPdeficient mouse as a model system to study underlying mechanisms in this disease.
Although abnormalities in ␤AR signaling have been postulated to promote cardiac dysfunction in the failing heart, other hypotheses have been suggested, which include altered Ca 2ϩ availability (21) , impaired ability of the L-type Ca 2ϩ channel to activate sarcoplasmic reticulum Ca 2ϩ release (22) , and abnormalities in myocyte cytoskeleton such as microtubular polymerization (23) . Although the precise mode of action by which overexpression of the ␤ARKct provides this salutary effect is not clear, it is unlikely to be a result of a nonspecific effect of transgene overexpression because cardiac overexpression of a ␤ 2 AR transgene in the MLP-deficient background had no effect on the heart failure phenotype. The strikingly opposite phenotypes observed with overexpression of the ␤ 2 AR and overexpression of the ␤ARKct suggests that marked chronic enhancement of ␤AR signaling by markedly increasing receptor number is not sufficient to prevent deterioration in cardiac function. In contrast, reversal of ␤ 1 AR desensitization through overexpression of a ␤ARK1 inhibitor acts to restore normal G protein coupling of the endogenous uncoupled ␤ 1 ARs. The lack of a beneficial effect with ␤ 2 AR transgene overexpression may in part be related to the extraordinarily high levels of receptor overexpression in those mice (15) or perhaps a result of different signaling properties of the ␤ 2 AR compared with the ␤ 1 AR (24). Furthermore, ␤ 2 AR overexpression in this model leads to constant maximal signaling (15) , whereas ␤ARKct overexpression preserves myocardial ␤AR responsiveness to endogenous catecholamine stimulation (11) . The deleterious effect of chronic ␤AR stimulation in the MLP Ϫ͞Ϫ ͞␤ 2 AR mice is consistent with the experience from clinical studies using oral inotropic agents in severe heart failure (25) . Our data suggest that restoring normal control of ␤ 1 AR signaling by inhibiting enhanced desensitization is an important mechanism to prevent the progressive deterioration in cardiac function in this model of heart failure. Interestingly, it has been shown recently that treatment with the ␤AR antagonist, carvedilol, can improve survival in human heart failure (26) . Although the mechanism(s) is not known, an intriguing basis for this beneficial effect of ␤AR antagonism may be the reduction of desensitization through lowering of ␤ARK1 levels (ref. 10; G.I., E. D. Tomhave, R.J.L., and W.J.K., unpublished results).
Because the ␤ARKct peptide inhibits ␤ARK1 activity via G ␤␥ sequestration, we cannot definitively exclude the possibility that inhibition of other G ␤␥ -dependent pathways contributes to the improved cardiac status of the MLP Ϫ͞Ϫ ͞ ␤ARKct animals. However, several lines of evidence argue strongly for inhibition of ␤ARK1 activity being the primary mechanism. First, the MLP Ϫ͞Ϫ ͞␤ARKct mice have increased ␤AR-coupling efficiency demonstrated by the increased isoproterenol-stimulated adenylyl cyclase activity and in vivo cardiac function, which clearly suggests inhibition of desensitization, just as would be expected for ␤ARK1 inhibition. Second, overexpression of the ␤ARKct does not prevent the development of cardiac hypertrophy in response to pressure overload but reverses ␤AR desensitization (9) , suggesting that other signaling pathways critical for the hypertrophic phenotype are unaffected by the ␤ARKct. Third, mice heterozygous for the ␤ARK1 gene deletion, which possess 50% less ␤ARK1 enzyme compared with wild-type animals, have a cardiac phenotype of enhanced contractility and sensitivity to ␤AR agonists (H.A.R., S. A. Akhter, D.-J.C., M. Jaber, R.J.L., M. G. Caron, and W.J.K. unpublished results) essentially identical to the ␤ARKct-overexpressing animals (11) . Finally, when the ␤ARKct transgenic mice were crossed into the ␤ARK1 heterozygous knockout background, this led to a further enhancement of cardiac function and isoproterenol responsiveness, which was associated with a stepwise decrement in G ␤␥ -dependent ␤ARK1 activity (H.A.R., S. A. Akhter, D.-J.C., M. Jaber, R.J.L., M. G. Caron, and W.J.K. unpublished results).
Other known actions of G ␤␥ (27, 28) such as activation of the I k.ach channel, adenylyl cyclase, PLC␤1-3, and MAP kinase appear not to be relevant in this situation. The I k.ach channel is located in atrial and not ventricular tissue and would not be expected to directly alter contractility (27, 29) . The isoforms of adenylyl cyclase that are regulated by G ␤␥ (I, II, IV) are not found in the heart (28). PLC␤ is not activated by myocardial ␤ARs (27) . Finally, in vivo activation of MAP kinase does not affect contractility (30) . Taken together, these data strongly suggest that the striking effects of the ␤ARKct indeed are mediated primarily through ␤ARK1 inhibition and restored ␤AR coupling and not through effects on other G ␤␥ -dependent pathways.
We do not, however, currently know whether the beneficial effect of ␤ARK1 inhibition also is mediated in part through reduction of desensitization of G protein-coupled receptors other than ␤ARs such as, for example, the angiotensin (18) or endothelin receptor. However, if this were the case, an opposite result would be expected. Inhibition of ␤ARK1 by the ␤ARKct would increase signaling through these pathways, whereas previous studies have demonstrated the marked benefit of blocking both angiotensin (31) and endothelin (32) signaling in heart failure.
The evidence we present here demonstrates the critical role that chronic ␤AR desensitization plays in the development of heart failure and the importance of preserving normal ␤AR coupling. That the inhibition of a single molecule (␤ARK1) can have such a dramatic effect on a cardiac phenotype caused by a structural abnormality (MLP deficiency) is surprising and indicates that ␤ARK1 inhibition may offer a novel therapeutic target in heart failure with the potential to have significant impact on this disease.
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